DNA interaction and cytotoxic activity of copper complex based on tridentate hydrazone derived ligand and nitrogen donor heterocycle

Isoxazole‐Derived Aroylhydrazones and Their Dinuclear Copper(II) Complexes Show Antiproliferative Activity on Breast Cancer Cells with a Potentially Alternative Mechanism Of Action

“…The K b constants for 1-4 are comparable to those reported for other copper(II) complexes. [40][41][42] The calculated K b values for the ligands and complexes were smaller than the binding constant of the conventional DNA intercalator ethidium bromide, EB (in the order of~10 5 M À 1 ). [43] Both ligands presented an emission band at 530 nm for H 3 L1 and 503 nm for H 2 L2 upon excitation at 350 nm).…”

Synthesis and physicochemical, DFT, thermal and DNA-binding analysis of a new pentadentate N3S2 Schiff base ligand and its [CuN3S2]2+ complexes

“…The resulting mixed solution of Cu(II)/CT-DNA was allowed to equilibrate for 10 min at RT for each experiment prior to carrying out the absorption measurement. [35][36][37][38][39]…”

“…Each sample was measured in triplicate and the average ow time was calculated. Data are presented as (h/h o ) 1/3 versus the binding ratio [Cu]/[DNA], [35][36][37][38][39][40][41] where h is the viscosity of DNA in the presence of the complex and h o is the viscosity of the pure DNA solution. The desired Cu(II) complexes were prepared by mixing an equivalent amount of N 3 S 2 with the hydrated CuX 2 salt in EtOH at RT under an atmosphere.…”

“…Absorption spectroscopy is considered to be one of the most useful methods to evaluate the DNA binding affinity of a molecule. [35][36][37][38][39][40] The affinity of complex 1 and 2 toward CT-DNA was investigated using the UV-Vis titration spectra recorded in Tris-HCl buffer solution. The UV-Vis spectra of the target compounds were expected to change upon drug-DNA binding.…”

DNA binding behaviour of mixed ligand vanadium(V) complex based on novel tridentate hydrazone and benzhydroxamic acid ligand systems

“…In this context, several structurally modified forms of cisplatin have been explored in addition to other metal‐based compounds in order to improve the therapeutic efficacy with no side effects . Thus, transition metal complexes of copper, zinc, ruthenium, palladium and vanadium based on various ligand systems have been successfully established as effective cytotoxic agents and are used as alternatives to platinum‐based compounds. The biological activity of metal complexes can be tuned based on the ligand system involved in the formation of the complex.…”